Seelos Therapeutics, Inc. (Seelos), a clinical-stage biopharmaceutical company, has filed a prospectus related to the resale of up to 3,404,256 shares of common stock by selling stockholders. These shares are issuable upon the exercise of outstanding warrants that were initially issued to the selling stockholders on January 30, 2024, under a Securities Purchase Agreement dated January 26, 2024. The warrants, exercisable at $1.05 per share, are currently exercisable and will expire on January 30, 2029. The filing of this prospectus is a regulatory step to register the resale of these shares, which does not necessarily indicate that the selling stockholders will immediately sell any or all of the shares. Seelos will not receive any proceeds from the sale of shares by the selling stockholders, except for potential...Show More

Seelos Therapeutics, Inc. (Seelos), a clinical-stage biopharmaceutical company, has filed a prospectus related to the resale of up to 3,404,256 shares of common stock by selling stockholders. These shares are issuable upon the exercise of outstanding warrants that were initially issued to the selling stockholders on January 30, 2024, under a Securities Purchase Agreement dated January 26, 2024. The warrants, exercisable at $1.05 per share, are currently exercisable and will expire on January 30, 2029. The filing of this prospectus is a regulatory step to register the resale of these shares, which does not necessarily indicate that the selling stockholders will immediately sell any or all of the shares. Seelos will not receive any proceeds from the sale of shares by the selling stockholders, except for potential proceeds from the cash exercise of warrants. The company's common stock is traded on the Nasdaq Capital Market under the symbol 'SEEL'. As of March 14, 2024, the last reported sale price per share was $1.05. The prospectus also includes details on the company's executive compensation, equity compensation plans, and certain relationships and related party transactions.